• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature >Combination therapy with anti-HIV-1 antibodies maintains viral suppression
【24h】

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

机译：抗HIV-1抗体联合治疗可维持病毒抑制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg(-1) of each antibody at 0, 3 and 6 weeks. Infusions of the two antibodies were generally well-tolerated. The nine enrolled individuals with antibody-sensitive latent viral reservoirs maintained suppression for between 15 and more than 30 weeks (median of 21 weeks), and none developed viruses that were resistant to both antibodies. We conclude that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.
机译：感染HIV-1的个体需要终生抗逆转录病毒疗法，因为治疗中断会导致快速反弹的病毒血症。在这里，我们报告了一项1b期临床试验，其中在分析治疗中断期间给予了3BNC117和10-1074，两种有效的单克隆抗HIV-1广泛中和抗体（针对HIV-1包膜刺的独立位点）的组合。在第0、3和6周时，参与者接受了每种抗体30 mg kg（-1）的3次输注。两种抗体的输注通常耐受良好。登记的9名具有抗体敏感潜伏病毒库的个体在15到30周以上（中位数为21周）内保持抑制，并且没有人开发出对两种抗体均具有抗性的病毒。我们得出结论，抗HIV-1单克隆抗体3BNC117和10-1074的组合可在缺乏抗逆转录病毒疗法的情况下在具有抗体敏感性病毒库的个体中维持长期抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号